Home > FDA MedWatch > FDA MedWatch – Zyvox (linezolid) or Methylene Blue

FDA MedWatch – Zyvox (linezolid) or Methylene Blue

Zyvox (linezolid) or Methylene Blue: Potential Drug Interaction with Serotonergic Psychiatric Medications

MedWatch updated our previous (07/26/2011) safety alerts on the potential drug interaction between linezolid or methylene blue and serotonergic psychiatric medications.

Not all serotonergic psychiatric drugs have an equal capacity to cause serotonin syndrome with linezolid or methylene blue. Most cases from the FDA’s Adverse Event Reporting System (AERS) of serotonin syndrome associated with linezolid occurred in patients taking specific serotonergic psychiatric drugs, including selective serotonin reuptake inhibitors (SSRI), or serotonin norepinephrine reuptake inhibitors (SNRI). Most cases from AERS of serotonin syndrome associated with methylene blue occurred in patients taking SSRIs, SNRIs, or clomipramine.

It is unclear at this time whether linezolid or methylene blue administration in patients receiving other psychiatric drugs with lesser degrees of serotonergic activity poses a comparable risk.

Read the MedWatch safety alert UPDATES:

Zyvox (linezolid): http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm265479.htm

Methylene Blue: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm265476.htm

  1. No comments yet.
  1. No trackbacks yet.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: